Emergent BioSolutions Inc. SEC filings EBS
Emergent BioSolutions Inc. has 1,001 filings in SEC EDGAR's recent list, going back to Dec 29, 2014. Its latest annual report, Form ARS, was filed on Mar 20, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Nov 3, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Nov 4, 2026 (other events). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| DEFA14A | Additional proxy material | Apr 28, 2026 | — |
| DEFA14A | Additional proxy material | Apr 27, 2026 | — |
| DEFA14A | Additional proxy material | Apr 22, 2026 | — |
| DEFA14A | Additional proxy material | Apr 16, 2026 | — |
| DEFA14A | Additional proxy material | Apr 16, 2026 | — |
| DEFA14A | Additional proxy material | Mar 20, 2026 | — |
| DEF 14A | Proxy statement | Mar 20, 2026 | Dec 31, 2025 |
| DEF 14A | Proxy statement | Mar 21, 2025 | Dec 31, 2024 |
| DEFA14A | Additional proxy material | Mar 21, 2025 | — |
| DEFA14A | Additional proxy material | Apr 11, 2024 | — |
| DEF 14A | Proxy statement | Apr 11, 2024 | May 23, 2024 |
| DEFA14A | Additional proxy material | Apr 14, 2023 | — |
| DEF 14A | Proxy statement | Apr 14, 2023 | — |
| DEFA14A | Additional proxy material | Apr 15, 2022 | — |
| DEF 14A | Proxy statement | Apr 15, 2022 | May 26, 2022 |
| DEFA14A | Additional proxy material | Apr 9, 2021 | — |
| DEF 14A | Proxy statement | Apr 9, 2021 | Apr 9, 2021 |
| DEFA14A | Additional proxy material | Apr 9, 2020 | — |
| DEF 14A | Proxy statement | Apr 9, 2020 | May 21, 2020 |
| DEFA14A | Additional proxy material | Apr 12, 2019 | — |
| DEF 14A | Proxy statement | Apr 12, 2019 | May 23, 2019 |
| DEFA14A | Additional proxy material | Apr 13, 2018 | — |
| DEF 14A | Proxy statement | Apr 13, 2018 | May 24, 2018 |
| DEFA14A | Additional proxy material | Apr 13, 2017 | — |
| DEF 14A | Proxy statement | Apr 13, 2017 | May 25, 2017 |
| DEF 14A | Proxy statement | Apr 8, 2016 | May 19, 2016 |
| PRE 14A | Preliminary proxy statement | Mar 25, 2016 | May 19, 2016 |
| DEF 14A | Proxy statement | Apr 10, 2015 | May 21, 2015 |
Showing 28 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- EBS (NYSE)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Gaithersburg, MD
- SEC filer status
- Accelerated filer
- SEC CIK
- 1367644
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.